Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.
RDY Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dr Reddys Laboratories Ltd. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 93th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 2803.17% on a DCF basis. The most interesting components of our discounted cash flow analysis for Dr Reddys Laboratories Ltd ended up being:
The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately only 11.39% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Dr Reddys Laboratories Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than merely 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RDY, try BEAT, OMI, CORT, FVE, and ALPN.
Dr. Reddy’s Laboratories ([[RDY]] -1.7%) says that the Drugs Control General of India ((DCGI)) has given it the go-ahead to conduct phase 3 clinical trial for the Sputnik V COVID-19 vaccine in India, a day ahead of the scheduled mass vaccination drive in the country.The phase 3 study of Sputnik V will be conducted...
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31, 2020 on Friday, January 29th, 2021 after the Board Meeting.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response Aid FZCO (GRA) today announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. REEQONUS™ is also known as Avigan® (favipiravir) Tablets, developed by FUJIFILM Toyama Chemical Co., Ltd.